Abstract
In the March 2020 issue of Thyroid (vol. 30, no. 3; pp. 357–364) the article entitled “Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study” by Brito et al. requires correction.
In the Treatment section “RAI (n = 1549)” of Table 3, the number of patients and percentage of patients have been updated, though the main text was correct.
The original table reads:
Frequency of Adverse Effects
Given to OptumLabs report policies, adverse events between 0 and 10 events could only be described as composite. This composite has been added to the total frequency of complication for each treatment modality.
Include acute and subacute necrosis of liver, drug-induced cholestasis, and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Include agranulocytosis, acute and subacute necrosis of liver, hepatitis, unspecified (includes drug induced).
Include hemorrhage, seroma, infection, vocal cord paralysis, and dysphonia.
Include hemorrhage, seroma, infection, vocal cord paralysis, dysphonia, and hypoparathyroidism.
The Table has been revised to:
Frequency of Adverse Effects
Given to OptumLabs report policies, adverse events between 0 and 10 events could only be described as composite. This composite has been added to the total frequency of complication for each treatment modality.
Includes acute and subacute necrosis of liver, drug-induced cholestasis, and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Includes agranulocytosis, acute and subacute necrosis of liver, hepatitis, unspecified (includes drug induced).
Includes hemorrhage, seroma, infection, vocal cord paralysis, and dysphonia.
Includes hemorrhage, seroma, infection, vocal cord paralysis, dysphonia, and hypoparathyroidism.
The online version has been corrected to reflect this. The authors apologize for these errors.